Kura Oncology officer Brian Powl plans 448-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. officer Brian Powl gave notice of a proposed sale of 448 common shares, with an aggregate market value of $3,288.32 and an approximate sale date of November 19, 2026. The form names Morgan Stanley Smith Barney LLC as broker and NASDAQ as the exchange.
The shares were acquired for cash through the Employee Stock Purchase Plan on November 17, 2026. The notice lists May 22, 2026 as the Rule 10b5-1 plan adoption or instruction date. The prior-three-month table includes a 15,254-share sale for gross proceeds of $113,639.25 on November 17, 2026 and a 15,430-share sale for gross proceeds of $165,852.44 on September 29, 2026; both entries are labeled 10b5-1 sales.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Employee Stock Purchase Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.